Loading...

OTLK OUTLOOK THERAPEUTICS INC Product Launches 8-K Filing

TLK

TLK

OUTLOOK THERAPEUTICS INC

(OTLK)

2026 8-K

Stock Offering Approved

FDA Appeal Success

Financial Results Announcement

Stock Offering Agreement

Equity Offering Update

FDA Meeting Update

FDA Dispute Resolution

Public Offering Launch

Note Purchase Agreement

Stockholder Meeting Results

FDA Meeting Update

Delisting Notification

Financial Results Report

FDA Meeting Request

FDA Response Letter

Financial Results Disclosed

FDA Acknowledgement

FDA Resubmission Update

FDA Meeting Update

Management Change

FDA Response Letter

Financial Results Released

New Product Launches

Equity Offerings

Financial Statements

FDA Acknowledgment

FDA Resubmission

Financial Results

Debt Financing Deal

Warrant Inducement

Financial Results

Workforce Reduction

Clinical Trial Results

Financial Results

Marketing Authorization Gra...

Earnings Reports

Headquarters Relocation

Private Placement

Agreement with BTIG

Compliance Notice from Nasdaq

Private Placement

Stock Authorization Increase

Earnings Reports

Private Placement and Note ...

Financial Results Announcement

Organizational Realignment

Update on Type A Meetings w...

Financial Results Announcement

Agreement with BTIG, LLC

Earnings Reports

Amendment to Articles of In...

Financial Results Announcement

External Links:

On May 26, 2026, Outlook Therapeutics, Inc. announced that the FDA granted its appeal following a dispute regarding its drug ONS-5010/LYTENAVA™, confirming its effectiveness for treating neovascular age-related macular degeneration. The company plans to resubmit its Biologics License Application in June 2026 as a Class 1 resubmission.

AI Assistant

OUTLOOK THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.